Organization | Commissariat A L'energie Atomique

Commissariat A L'energie Atomique Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial

2011

NCT01377220

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Commissariat A L'energie Atomique | Commissariat Ã l'Energie Atomique

Active Ingredients

Drugs in Phase 3 Trials (11)

capmatinib (Tabrecta) (1 trial)

ceritinib (zykadia) (1 trial)

dabrafenib (tafinlar) (1 trial)

durvalumab (imfinzi) (1 trial)

futibatinib (Lytgobi) (1 trial)

glasdegib (Daurismo) (1 trial)

lapatinib (tykerb) (1 trial)

nilotinib (tasigna) (1 trial)

olaparib (lynparza) (1 trial)

palbociclib (ibrance) (1 trial)

trametinib (mekinist) (1 trial)

Drugs in Phase 2 Trials (1)

choline c11 (choline c-11) (1 trial)

Drugs in Other Trials (1)

albuterol (proventil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Sarcoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 13